Track topics on Twitter Track topics that are important to you
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
DelveInsight's, Zeclar API Insights, 2017 Report provides marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File USDMF and Europe DMF filed by worldwide countries related to the drug. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research, analysis also presents the global sales data till 2016.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.
A review of the Zeclar based on information derived from company and industryspecific sources
Coverage of the Marketed data of the Zeclar on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
Coverage of the United States Drug Master File US DMF, Active Substance Master File/EU DMF and API Manufactures in China India for drug with location details.
Patent Expiry Timeline and Exclusivity Details
Global Sales Figure from 20122016
Qualitative and quantitative assessment of market spaceReasons to buy
Evaluate the marketing status and exclusivity details of Zeclar to exploit opportunities for generic drug development opportunities.
Design effective counterstrategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Zeclar.
API intelligence over Zeclar and gaining primary intelligence over Active Ingredients manufacturers across the globe.
Uncovering opportunities in the rapidly growing the US market
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your MA and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and indepth analysis of the drug's performance
Original Article: ZeclarAPI Insights, 2017 [Updated: 30052017] Prices from USD $425NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...